title: Diseases of abnormal sensitivity to cold in children on psychostimulant drugs.
abstract: BACKGROUND
  Oral psychostimulant (PS) drugs, the pharmacologic treatment of choice for attention-deficit/hyperactivity disorder (ADHD), have been associated with diseases of abnormal sensitivity to cold (DASC) such as Raynaud phenomenon and acrocyanosis.
  
  
  OBJECTIVE
  In a cohort of pediatric patients with DASC, we sought to identify prevalence and clinical features of patients on PS drugs.
  
  
  METHODS
  A 6-year retrospective chart review (2005-2011) of Ste-Justine University Hospital Center DASC patients with and without exposure to PS drugs was performed. Clinical data were analyzed with descriptive statistical methods.
  
  
  RESULTS
  Of 43 patients with DASC, 11 (25%) were exposed to PS drugs. In this group males were overrepresented, there was no evidence of collagen vascular diseases, serologic findings were not significant and the mean duration of PS intake was of 2.5 years. DASC age of onset was similar in both exposed and nonexposed patients. The incidence of more than one DASC type was greater in teenager patients with a positive family history of autoimmune and/or collagen vascular diseases.
  
  
  CONCLUSIONS
  This study is limited by its small population size, short follow-up period and its retrospective nature.
  
  
  CONCLUSIONS
  Physicians should be aware of PS drugs as possible triggers for DASC.
authors.affiliation: Pediatric Dermatology Division and Department of Pharmacy, CHU Ste-Justine, Montreal, PQ jerome.coulombe@umontreal.ca.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Coulombe
authors.affiliation: Pediatric Dermatology Division and Department of Pharmacy, CHU Ste-Justine, Montreal, PQ.
authors.forename: Julie
authors.initials: J
authors.lastname: Powell
authors.affiliation: Pediatric Dermatology Division and Department of Pharmacy, CHU Ste-Justine, Montreal, PQ.
authors.forename: Afshin
authors.initials: A
authors.lastname: Hatami
authors.affiliation: Pediatric Dermatology Division and Department of Pharmacy, CHU Ste-Justine, Montreal, PQ.
authors.forename: Catherine
authors.initials: C
authors.lastname: McCuaig
authors.affiliation: Pediatric Dermatology Division and Department of Pharmacy, CHU Ste-Justine, Montreal, PQ.
authors.forename: Sophie
authors.initials: S
authors.lastname: Renet
authors.affiliation: Pediatric Dermatology Division and Department of Pharmacy, CHU Ste-Justine, Montreal, PQ.
authors.forename: Danielle
authors.initials: D
authors.lastname: Marcoux
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015995:Prevalence; D011792:Quebec / Q000453:epidemiology; D012189:Retrospective Studies; D020886:Somatosensory Disorders / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D000697:Central Nervous System Stimulants